Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 2905 |
| INN | Vecantoxatug |
| Status | Clinical |
| Drug code(s) | GR2001 |
| Brand name | None |
| mAb sequence source | mAb - source TBD |
| General Molecular Category | TBD |
| Format, general category | TBD |
| Format details | None |
| Isotype (Fc) | TBD |
| Light chain isotype | TBD |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | None |
| Target(s) | Tetanus toxin |
| Indications of clinical studies | Tetanus prophylaxis |
| Primary therapeutic area | Infectious diseases |
| Most advanced stage of development (global) | Phase 3 |
| Status | Active |
| Start of clinical phase (IND filing or first Phase 1) | August 27, 2022 |
| Start of Phase 2 | March 15, 2023 |
| Start of Phase 3 | September 03, 2024 |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | Genrix (Shanghai) Biopharmaceutical Co., Ltd. |
| Licensee/Partner | None |
| Comments about company or candidate | Breakthrough Therapy designation in China. NCT06635798 CTR20243076 Phase 3 started in Sep 2024. NCT06302374 Phase 1/2 started in Mar 2023. CXSL2200485 has event date of Sep 27, 2022. |
| Full address of company | Shanghai, China Asia China https://synapse.patsnap.com/organization/575cf201cc223eac2f65ac65cddb2931 |
Listed as mAbs in company pipeline (http://www.genrixbio.com/#/science?classId=class3)
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |